Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Gynecologic 1

Conditions

Breast Neoplasms 310Neoplasm Metastasis 38Neoplasms 22Ovarian Neoplasms 18Advanced Breast Cancer 18Carcinoma, Non-Small-Cell Lung 14Endometrial Neoplasms 11Prostatic Neoplasms 10Hereditary Sensory and Autonomic Neuropathies 10Triple Negative Breast Neoplasms 8Colorectal Neoplasms 6Breast Cancer Metastatic 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Carcinoma, Ovarian Epithelial 5Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Breast Diseases 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Lobular 3Uterine Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Recurrence × Fulvestrant × Clear all
NCT07062965 2026-05-06

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Pfizer

Phase 3 Recruiting
400 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT05154487 2026-03-03

A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled

Recurrence

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Pfizer

Phase 2 Active not recruiting
333 enrolled
Breast

Breast Neoplasms, Recurrence

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed
514 enrolled 13 charts
Breast

Breast Neoplasms, Neoplasms, Recurrence

NCT00334295 2012-07-31

Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

AstraZeneca

Phase 2 Completed
35 enrolled 9 charts
Gynecologic

Recurrence, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡